Home Cart Sign in  
Chemical Structure| 50679-08-8 Chemical Structure| 50679-08-8

Structure of Terfenadine
CAS No.: 50679-08-8

Chemical Structure| 50679-08-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Terfenadine is a potent open-channel blocker of hERG with a mean IC50 of 204 nM.

Synonyms: MDL-991; NSC 665802; Terfen

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Terfenadine

CAS No. :50679-08-8
Formula : C32H41NO2
M.W : 471.67
SMILES Code : CC(C)(C1=CC=C(C(CCCN2CCC(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)CC2)O)C=C1)C
Synonyms :
MDL-991; NSC 665802; Terfen
MDL No. :MFCD00079622
InChI Key :GUGOEEXESWIERI-UHFFFAOYSA-N
Pubchem ID :5405

Safety of Terfenadine

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H361-H372-H410
Precautionary Statements:P201-P264-P280-P301+P330+P331-P312
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01940393 Urticaria Phase 4 Completed - Colombia ... More >> Medellin Medellin, Antioquia, Colombia Less <<
NCT02056743 Healthy Phase 1 Completed - Korea, Republic of ... More >> Clinical Trial Center of Chonbuk National University Hospital Jeonju, Jeollabuk-do, Korea, Republic of Less <<
NCT02966665 Chronic Obstructive Pulmonary ... More >>Disease Pulmonary Artery Hypertension Heart Failure Hypertension Less << Phase 1 Recruiting August 2020 United States, Utah ... More >> George E Wahlen VA Medical Center Recruiting Salt Lake City, Utah, United States, 84132 Contact: Russell Richardson, Ph.D.    801-582-1565    r.richardson@hsc.utah.edu    Contact: Ashley Nelson, MD    801-582-1565 ext 4127    ash.nelson@hsc.utah.edu Less <<
NCT02391688 Drug Interaction Phase 1 Completed - Switzerland ... More >> Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4 Genève, Switzerland, 1211 Less <<
NCT00637585 Allergic Rhinitis Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT02171546 Healthy Phase 1 Terminated - -
NCT01683552 ITCH Phase 2 Completed - Italy ... More >> Campus Bio-Medico of Rome University Roma, Italy, 00128 Less <<
NCT00783146 Seasonal Allergic Rhinitis Phase 4 Completed - -
NCT02551536 Allergic Rhinitis Phase 4 Completed - -
NCT00783211 Seasonal Allergic Rhinitis Phase 4 Completed - -
NCT03012763 Pharmacokinetics ... More >> Magnetic Resonance Imaging Administration, Oral Less << Phase 1 Completed - -
NCT01133470 Healthy Phase 1 Completed - India ... More >> Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujrat, India, 380015 Less <<
NCT01586091 Allergic Rhinitis Phase 1 Completed - Germany ... More >> University of Berlin Charité Berlin, Germany, 10117 Less <<
NCT01306721 Rhinitis Seasonal Phase 3 Completed - Japan ... More >> Investigational Site Number 392002 Koganei-Shi, Japan Investigational Site Number 392003 Osaka-Shi, Japan Investigational Site Number 392001 Shinjuku-Ku, Japan Less <<
NCT03108274 Drug Interaction Potentiation Phase 1 Completed - New Zealand ... More >> Auckland Clinical Studies Auckland, New Zealand, 1150 Less <<
NCT02175485 Rhinitis Allergic Phase 4 Completed - Japan ... More >> Investigational Site Number 392-001 Shinjuku-ku, Japan Less <<
NCT00420082 Seasonal Allergic Rhinitis Phase 2 Completed - Austria ... More >> Allergy Center Vienna West Vienna, Austria, A-1150 Less <<
NCT01133483 Healthy Phase 1 Completed - India ... More >> Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujrat, India, 380015 Less <<
NCT00435461 Rhinitis, Allergic, Seasonal Phase 4 Completed - United States, Texas ... More >> GSK Investigational Site Austin, Texas, United States, 78731 GSK Investigational Site Austin, Texas, United States, 78750 GSK Investigational Site Kerrville, Texas, United States, 78028 GSK Investigational Site New Braunfels, Texas, United States, 78130 GSK Investigational Site San Antonio, Texas, United States, 78205 GSK Investigational Site San Antonio, Texas, United States, 78229 Less <<
NCT00045955 Asthma Phase 3 Completed - United States, New Jersey ... More >> Aventis Pharmaceutical Inc. Bridgewater, New Jersey, United States, 08807 Less <<
NCT00502775 Rhinitis, Allergic, Seasonal Phase 4 Completed - -
NCT00636870 Allergic Rhinitis Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT00502775 - Completed - -
NCT00637611 Seasonal Allergic Rhinitis Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT00435461 - Completed - -
NCT00637455 Seasonal Allergic Rhinitis Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT00783133 Seasonal Allergic Rhinitis Phase 4 Completed - -
NCT00794768 Seasonal Allergic Rhinitis Phase 4 Completed - -
NCT00794248 Seasonal Allergic Rhinitis Phase 4 Completed - -
NCT00638118 Allergic Rhinitis Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT01469234 - Completed - -
NCT01852318 Uremic Pruritus Phase 4 Unknown May 2015 Taiwan ... More >> National Taiwan University (NTUH); NTUH Hsin-Chu Branch; NTUH Yun-Lin Branch; Cathay General hospital Not yet recruiting Taipei, Taiwan, 100; 300; 640; 280 Contact: Hsien-Yi Chiu, MD    0972654317    extra.owl0430@yahoo.com.tw    Principal Investigator: Hsien-Yi Chiu, MD Less <<
NCT01526213 Food-drug Interaction Not Applicable Completed - United States, North Carolina ... More >> North Carolina Clinical and Translational Research Center Chapel Hill, North Carolina, United States, 27599 Less <<
NCT02908750 Non Small Cell Lung Cancer Phase 1 Active, not recruiting March 13, 2019 France ... More >> Research Site Rennes Cedex 9, France, 35033 Korea, Republic of Research Site Seongnam-si, Korea, Republic of, 13620 Research Site Seoul, Korea, Republic of, 05505 Spain Research Site Madrid, Spain, 28040 Research Site Madrid, Spain, 28046 Research Site Madrid, Spain, 28050 Research Site Sevilla, Spain, 41013 Less <<
NCT03183297 Veisalgia Phase 1 Not yet recruiting December 2017 -
NCT00044811 Asthma Phase 3 Completed - United States, New Jersey ... More >> Aventis Pharmaceuticals Inc. Bridgewater, New Jersey, United States, 08807 Costa Rica Sanofi-Aventis Admnistrative Office Costa Rica, Costa Rica Guatemala Sanofi-Aventis Administrative Office Guatemala City, Guatemala Hungary Sanofi-Aventis Administrative Office Budapest, Hungary Mexico Sanofi-Aventis Administrative Office Mexico, Mexico Poland Sanofi-Aventis Administrative Office Warszawa, Poland Russian Federation Sanofi-Aventis Administrative Office Moscow, Russian Federation Less <<
NCT01469234 Rhinitis Phase 4 Completed - -
NCT00044824 Asthma Phase 3 Completed - United States, New Jersey ... More >> Aventis Pharmaceuticals Inc. Bridgewater, New Jersey, United States, 08807 Costa Rica Sanofi-Aventis Admnistrative Office Costa Rica, Costa Rica Guatemala Sanofi-Aventis Administrative Office Guatemala City, Guatemala Hungary sanofi-aventis Hungaria Budapest, Hungary Mexico Sanofi-Aventis Administrative Office Mexico, Mexico Poland sanofi-aventis Poland Warszawa, Poland Russian Federation Sanofi-Aventis Aministrative Office Moscow, Russian Federation Less <<
NCT01526213 - Completed - -
NCT00261079 Pruritus Phase 4 Completed - Korea, Republic of ... More >> Handok Seoul, Korea, Republic of Less <<
NCT00562120 Allergic Rhinitis Phase 2 Completed - United States, Nebraska ... More >> Pfizer Investigational Site Omaha, Nebraska, United States, 68131 Less <<
NCT00637884 Cat Induced Allergic Rhinitis Phase 4 Completed - -
NCT00562120 - Completed - -
NCT00649376 Healthy Phase 1 Completed - United States, West Virginia ... More >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 Less <<
NCT00647985 Healthy Phase 1 Completed - United States, West Virginia ... More >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 Less <<
NCT00547768 Allergy Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT00741897 Rhinitis, Allergic, Perennial Phase 4 Completed - Philippines ... More >> Sanofi-aventis administrative office Makati City, Philippines Less <<
NCT00835276 - Completed - -
NCT00835640 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58102 Less <<
NCT01033396 Allergic Rhinitis Phase 2 Completed - Canada, Ontario ... More >> Pfizer Investigational Site Kingston, Ontario, Canada, K7L 2V7 Less <<
NCT01066754 Healthy Phase 1 Completed - Canada ... More >> Anapharm Inc., Sainte-Foy Quebec, Canada, G1V 2K8 Less <<
NCT01066767 Healthy Phase 1 Completed - Canada ... More >> Anapharm Inc., Sainte-Foy Quebec, Canada, G1V 2K8 Less <<
NCT00835276 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58102 Less <<
NCT01172522 - Completed - -
NCT00835640 - Completed - -
NCT01888718 Healthy Phase 1 Completed - India ... More >> Bioserve Clinical Research Private Limited Balanagar, Hyderabad, Andhra Pradesh, India, 500 037 Less <<
NCT01767272 Healthy Not Applicable Completed - -
NCT01172522 Edema Phase 2 Completed - United States, New Jersey ... More >> TKL Research Paramus, New Jersey, United States, 07652 Less <<
NCT01298505 Healthy Phase 1 Terminated(This study was stop... More >>ped due to lack of evidence for clinical efficacy.) Less << - Singapore ... More >> Pfizer Investigational Site Singapore, Singapore, 188770 Less <<
NCT03078777 Hemodialysis Phase 4 Recruiting August 2020 Canada, Ontario ... More >> London Health Sciences Centre Recruiting London, Ontario, Canada, N6A5A5 Contact: Brad Urquhart, PhD    5196613756    Brad.Urquhart@schulich.uwo.ca Less <<
NCT02157558 Drug Interactions Phase 1 Completed - United States, Texas ... More >> Lexicon Investigational Site Dallas, Texas, United States, 75247 Less <<
NCT03664882 Rhinitis Seasonal Phase 3 Recruiting February 2019 Canada ... More >> Investigational Site Number Recruiting Canada, Canada Less <<
NCT00699894 Postoperative Nausea and Vomit... More >>ing Less << Not Applicable Withdrawn(Logistical difficult... More >>ies running the study) Less << - United States, New York ... More >> Long Island Jewish Medical Center/Schneider's Children Hospital New Hyde Park, New York, United States, 11040 Less <<
NCT03425097 Gastroesophageal Reflux Phase 2 Recruiting May 2019 United States, California ... More >> Silicon Valley Gastroenterology 2490 Hospital Dr. Suite 211 Recruiting Mountain View, California, United States, 94040 Contact: George Triadafilopoulos, MD    650-988-7530    vagt@stanford.edu Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.12mL

0.42mL

0.21mL

10.60mL

2.12mL

1.06mL

21.20mL

4.24mL

2.12mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories